Broncus Holding (2216) Fundamentals 2026 — Revenue Analysis | SniperIQ
Broncus Holding (2216) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of HK
Broncus Holding (2216) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of HK
Broncus Holding (2216) has a market capitalization of approximately HK
Broncus Holding's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Broncus Holding runs a net profit margin of -10273.0%, a gross margin of -1585.1%, and an operating margin of -14017.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Broncus Holding reported revenue of
Broncus Holding does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Broncus Holding carries a debt-to-equity ratio of 0.00x and a current ratio of 22.70x, with a market beta of 1.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Broncus Holding (2216) the key facts are: market cap HK
Get Broncus Holding's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.